Claudin-like protein 24 interacts with the VEGFR-2 and VEGFR-3 pathways and regulates lymphatic vessel development

Pipsa Saharinen1,2,8 Hanna Helotera1,3,4,5,8 Juho Miettinen1,3,4,5 Camilla Normen1,3,4,5 Gabriela D’Amico1,3,4,5 Michael Jetsch1,3,4,5 Tobias Langenberg6,7 Wouter Vandevelde6,7 Annelii Ny6,7 Mieke Dewerchin6,7 Peter Carmeliet6,7 and Kari Alitalo1,3,4,5,9

1Molecular/Cancer Biology Program, Biomedicum Helsinki, University of Helsinki, Helsinki FIN-00014, Finland; 2Department of Virology, Haartman Institute, University of Helsinki, Helsinki FIN-00014, Finland; 3Department of Pathology, Haartman Institute, University of Helsinki, Helsinki FIN-00014, Finland; 4Institute for Molecular Medicine Finland, University of Helsinki, Helsinki FIN-00014, Finland; 5Helsinki University Central Hospital, University of Helsinki, Helsinki FIN-00014, Finland; 6Vesalius Research Center (VRC), VIB, 3000 Leuven, Belgium; 7Vesalius Research Center (VRC), K.U. Leuven, 3000 Leuven, Belgium

The Claudin-like protein of 24 kDa (CLP24) is a hypoxia-regulated transmembrane protein of unknown function. We show here that clp24 knockdown in Danio rerio and Xenopus laevis results in defective lymphatic development. Targeted disruption of Clp24 in mice led to enlarged lymphatic vessels having an abnormal smooth muscle cell coating. We also show that the Clp24+/− phenotype was further aggravated in the Vegfr2+/LacZ or Vegfr3+/−/LacZ backgrounds and that CLP24 interacts with vascular endothelial growth factor receptor-2 (VEGFR-2) and VEGFR-3 and attenuates the transcription factor CREB phosphorylation via these receptors. Our results indicate that CLP24 is a novel regulator of VEGFR-2 and VEGFR-3 signaling pathways and of normal lymphatic vessel structure.

Supplemental material is available at http://www.genesdev.org.

Received October 28, 2009; revised version accepted March 5, 2010.

The lymphatic vasculature is required for tissue fluid balance and immune system function (Tammela and Alitalo 2010). Dysfunction of the lymphatic system can lead to lymphedema, characterized by swelling of extremities due to fluid accumulation in tissues. Lymphatic vessels also represent the primary route of metastatic spread for many types of human cancers, and they are intimately involved in various inflammatory disorders. The development of the lymphatic vasculature in mice starts at around embryonic day 10.5 (E10.5), after the formation of a functional cardiovascular system (Adams and Alitalo 2007; Tammela and Alitalo 2010). Vascular endothelial growth factor-C (VEGF-C) induces lymphatic sprouting by activating the VEGF receptor-3 (VEGFR-3) on the surface of the first differentiated lymphatic endothelial cells (Karkkainen et al. 2004). VEGFR-3 is expressed initially in all endothelial cells of mouse embryos, but becomes restricted to the lymphatic endothelium during development (Tammela and Alitalo 2010). Some lymphangiogenic signals are also mediated by VEGFR-2, which is expressed in blood vessels, collecting lymphatic vessels, and also lymphatic capillaries undergoing lymphangiogenesis, for example, in tumors (Nagy et al. 2002; Hirakawa et al. 2005; Wirzenius et al. 2007). The further remodeling and maturation of the lymphatic vasculature require several other molecules (e.g., Nrp2, podoplanin, Foxc2, Syk, SLP76, Angpt2, and Angpt14) (Adams and Alitalo 2007; Tammela and Alitalo 2010).

In order to better understand the development of the lymphatic vasculature, we searched for genes involved in lymphangiogenesis by carrying out a genome-wide gene expression analysis of primary human lymphatic endothelial cells (LECs) and blood vascular endothelial cells (BECs). Here we report on one of the genes enriched in LECs, the hypoxia-inducible Claudin-like protein of 24 kDa (CLP24, TMEM204). We show that CLP24 is essential for lymphatic development in zebrafish, frogs, and mice. Interestingly, CLP24 interacted with VEGFR-2 and VEGFR-3 and attenuated VEGF- and VEGF-C-induced phosphorylation of the transcription factor CREB, suggesting that CLP24 is a modulator of VEGFR-2 and VEGFR-3 signals required for lymphatic vascular development.

Results and Discussion

Endothelial expression of CLP24

To search for genes enriched in LECs, we compared the gene expression profiles of cultured LECs and BECs from human skin microvasculature using oligonucleotide arrays. We identified the CLP24 mRNA, which was expressed more abundantly in LECs than BECs cultured in vitro (Supplemental Fig. S1A) and from freshly ex vivo isolated microvascular endothelium (LEC vs. BEC fold: 5.8×, P = 0.004) [Wick et al. 2007]. All tested human tissues except the bone marrow and peripheral blood contained CLP24 mRNA of 1.9 kb, with enhanced levels in highly vascularized tissues such as the heart, lung, kidney, adrenal gland, and placenta [Supplemental Fig. S1B]. We confirmed that CLP24 is a hypoxia-regulated gene (Supplemental Fig. S1C; Kearsey et al. 2004). CLP24 was conserved in all species, including humans, mice, zebrafish, and frogs [Supplemental Fig. S1D,E].

We found that most of the Clp24 expression occurred in blood vessels at E10.5, E15.5, and E16.5 (Fig. 1A–D; Supplemental Figs. S2A–D, S3). In a screen of novel
cardiac genes, the Clp24 transcript was detected previously in the developing vascular system before E9.5 (Christofoorou et al. 2008). Notably, the expression pattern of Vegfr2 was very similar to that of Clp24. At E10.5, Clp24 and Vegfr2 were both observed in, e.g., intersomitic vessels (Fig. 1A,B, arrowheads), while only Vegfr2 was detected in larger vessels, such as the cardinal vein (Fig. 1A,B, arrows). At E10.5, Clp24 was also detected in the developing limb buds and branchial arches. At E15.5 and E16.5, Clp24 and Vegfr2 were prominent in the blood vessels, e.g., in the brain and developing limb bud (Fig. 1C,D, Supplemental Figs. S2A–D, S3). However, Clp24 mRNA was absent from the neural retina, where Vegfr2 was expressed (Supplemental Fig. S3, arrowheads).

Clp24 has been suggested to be a distant member of the claudin family of transmembrane proteins, which are engaged in homotypic interactions across the cell–cell junctions [Kearsey et al. 2004]. We confirmed that overexpressed Clp24 is localized at cell–cell junctions in epithelial cells (arrowheads in C), but not in endothelial (arrows in F, L) cells. (K, L) clp24 ISH of D. rerio embryos shows expression in the vasculature at the indicated hours post-fertilization [hpf]. (DA) Dorsal aorta. Bar, 20 μm.

Figure 1. Endothelial expression of CLP24. (A, B) Whole-mount ISH of E10.5 mouse embryos. Clp24 is expressed in ISVs similarly to Vegfr2. Arrows indicate the cardinal vein, and arrowheads indicate the ISVs. (C, D) Clp24 ISH of E16.5 mouse hindlimb and tail. (E–G) MDCK cells transfected with CLP24-EGFP and CLP24-V5 retroviruses were stained with anti-V5 antibody. (H–J) HDMECs transfected with CLP24-EGFP [H] retroviruses were stained with anti-β-catenin (I) and anti-PROX1 (J) antibodies to identify LECs (asterisks in H). Nuclei are stained with DAPI. CLP24 is localized to cell–cell junctions in epithelial cells (arrowheads in C), but not in endothelial (arrowheads in F, L) cells. (K, L) clp24 ISH of D. rerio embryos shows expression in the vasculature at the indicated hours post-fertilization [hpf]. (DA) Dorsal aorta. Bar, 20 μm.

clp24 is required for lymphatic vessel development in Danio rerio and Xenopus laevis

In order to elucidate the biological function of CLP24, we studied it in zebrafish and frog embryos. In situ hybridization [ISH] on early embryos showed that the D. rerio clp24 homolog (tmem204) was expressed initially in the dorsal aorta, and later also in the posterior cardinal vein [PCV] and intersegmental vessels [ISVs] (Fig. 1K,L). The knockdown of clp24 using 6–8 ng of morpholino [MO] directed against the 5′ untranslated region [UTR] of clp24 mRNA caused a subtle blood vascular defect, characterized by abnormal extra branching of the ISVs, but only from 4 d post-fertilization [dpf] onward, thus after the initiation of lymphatic development (Fig. 2A–D). The most striking defect was the impaired formation of the lymphatic thoracic duct [TD] [6 dpf] and its immediate precursor structure, the parachordal lymphangioblasts [48 h post-fertilization [hpf]] in clp24 morphants. The penetrance and severity of these defects were dose-dependent (Fig. 2E,F), and the results were confirmed using a second clp24 MO targeted against the translation start site (Supplemental Fig. S4A,B). Thus, the striking lymphatic defect occurred prior to the appearance of the subtle blood vascular defects.

Twenty nanograms to 60 ng of the clp24 MO resulted in lymphatic and blood vascular defects of X. laevis embryos in a dose-dependent manner [Supplemental Fig. S4A]. Live screening at stage 45 [Fig. 2G,H] showed edema in the heart, gut, and cloaca region in 58% of the clp24 morphants versus 7% of control MO-injected tadpoles [P < 0.0001], and blood flow arrest in 32% of clp24 morphants versus 3% of controls [P < 0.0001] despite normal beating of the heart and lymph hearts. In addition, 21% of the clp24 morphants had blood spots in their tissues versus 0% of controls [P < 0.0001].

To further characterize the phenotypes, knockdown of clp24 was performed in transgenic Tg(Flk1:eGFP) frogs that express eGFP in their blood and lymphatic vessels. Neither the ventral caudal lymphatic vessel [VCLV] nor the dorsal caudal lymphatic vessel [DCLV] assembled into a compact lymph vessel, and the LECs appeared dispersed and disorganized (Fig. 2I,J) in the clp24 morphants.

Staining for the lymphatic marker prox1 [Ny et al. 2005] at stage 35/36 revealed decreased commitment (−19%) toward the lymphatic lineage at the level of the PCV [prox1 area: 35,800 ± 1266 μm² in control tadpoles [n = 69] vs. 29,100 ± 1392 μm² in clp24 morphants [n = 58, P = 0.001]] (Fig. 2M,N). Fewer prox1-positive cells were...
CLP24, VEGFR-2, and VEGFR-3 in lymphatic development

Figure 2. Clp24 is required for vascular and lymphatic development in *D. rerio* and *X. laevis*. [A–D] Control-injected ([A,C] and clp24 MO-injected ([B,D]) embryos of a fluorescent zebrafish ([Flk1:eGFP]) line were screened at 6 dpf ([A,B]) and 48 hpf ([C,D]). Note extra branching of the ISVs (arrows in [B]) and absence of TD (arrowheads in [B]) at 6 dpf, and absence of parachordal lymphatic precursors (PL) ([arrow in C] in clp24 morphants [arrowheads in D]). (E,F) TD formation in clp24 morphants. (E) Percentage of affected embryos. (F) Average TD length over 10-somite tail segment at 6 dpf. *P < 0.05 versus control. ([G,H]) At stage 46, clp24 MO-treated ([H]) but not control-treated ([G]) *X. laevis* tadpoles had massive edema in heart, gut, and cloaca region (arrowheads). ([I–L]) Transgenic Tg(Flik1:eGFP) *X. laevis* embryos were injected with 40 ng of clp24 ([I,L]) or control MO ([I,K]). ([J]) Small capillaries, but not the main blood vessels, were to a large extent missing in clp24 morphants (arrowheads). ([F]) Both the VCLV and the DCLV failed to assemble into a compact lymph vessel, and the LECs appear dispersed and disorganized. [K,L] Lymphangiography for MO-treated tadpoles. Note the absence of dye uptake by the malformed VCLV in clp24 morphants [arrowhead, L] as compared with control [arrowheads, K]. ([M,N]) Control ([M]) and clp24 [N] MO-treated *X. laevis* embryos were analyzed at stage 35/36 by prox1 ISH. The clp24 morphants show less staining in the PCV, heart [H], and rostral lymph sac [RLS], and in the area of the future lymph hearts (LH) and of the future VCLV. Note a reduced number of prox1-positive cells migrating across the tail from the VCLV to form the DCLV [arrowheads]. Staining in liver [L] seems similar to control. ([DA]) Dorsal aorta; [DLAV] dorsal longitudinal anastomosing vessel.

Clp24 gene targeted mice have enlarged lymphatic vessels with abnormal smooth muscle cell (SMC) coverage

In order to reveal the in vivo function of Clp24 in mammals, we produced gene targeted Clp24 mice in which the first exon of the gene was flanked by loxP sites [Supplemental Fig. S5]. We crossed the Clp24lox/lox mice with the PGK-Cre mice to delete Clp24 in all tissues [Lallemand et al. 1998]. *Clp24lox/lox* mice were born in a normal Mendelian ratio, and survived until adulthood with no obvious health problems. However, immunohistochemical analysis of the vasculature of the *Clp24lox/lox* mice showed enlarged lymphatic vessels in various organs [Fig. 3A–E; Supplemental Figs. S6, S8I, S9C,D], while the blood capillary network appeared similar to that in wild-type littermates [Supplemental Fig. S9A,B,E–H].

Closer analysis of the ear vasculature showed that the collecting lymphatic vessels located in the deeper layers of the ears of the *Clp24lox/lox* mice were dilated when compared with wild-type littermates, but were equally covered by a continuous layer of SMC actin [SMA]-positive perivascular support cells [Fig. 3D,E, Supplemental Fig. S6C,D, arrowheads]. In the more superficial layers of the ear, the lymphatic vessels gradually lose the SMC coating, and express LYVE-1 [Supplemental Fig. S6B,D]. However, in the *Clp24lox/lox* mice, the enlarged initial lymphatic vessels had increased numbers of associated SMCs when compared with wild type [Fig. 3E, Supplemental Fig S6A–D, arrow]. Notably, LYVE-1 expression was down-regulated in the *Clp24lox/lox* lymphatic vessels in the sites that were in contact with SMCs, suggesting that SMCs modulated the lymphatic vessel identity [Supplemental Fig S6A, arrow]. We also mated the *Clp24lox/lox* mice with the Tie1-Cre mice, which results in deletion of Clp24 in endothelial cells. Importantly, the lymphatic phenotype of the endothelial cell-specific *Clp24lox/lox* knockout mice (*Clp24EClox/lox*) was similar to that of the *Clp24lox/lox* mice [Supplemental Fig. S7], strongly suggesting that endothelial cell-expressed Clp24 specifically contributes to the formation of the lymphatic vasculature.

CLP24 interacts with the VEGFR-2 and VEGFR-3 pathways in lymphatic vessel patterning

In order to analyze possible involvement of CLP24 in VEGFR-2 or VEGFR-3 pathways, we mated the *Clp24lox/lox* mice with *Vegfr2<sup>-/-</sup>LacZ* and *Vegfr3<sup>-/-</sup>LacZ* mice. The enlarged lymphatic vessels of the *Clp24lox/lox* mice were even more dilated in the *Vegfr3<sup>-/-</sup>LacZ* and *Vegfr2<sup>-/-</sup>LacZ* backgrounds [Supplemental Fig. S8A–F]. Notably, normal-sized lymphatic vessels of the *Clp24lox/lox* mice were dilated upon deletion of one allele of either *Vegfr2* or *Vegfr3*. Staining for β-galactosidase showed no abnormalities in the blood vasculature of the *Clp24lox/lox*/+*Vegfr2<sup>-/-</sup>LacZ* mice [Supplemental...
These results indicated that CLP24 modulates signaling via both VEGFR-2 and VEGFR-3. Our results show that CLP24 is essential for lymphatic development in frogs, zebrafish, and mice. The lymphatic vessels of the Clp24+/− mice were dilated and showed abnormal recruitment of SMCs, while in the frog and zebrafish, the lymphatic development appeared to fail altogether. In zebrafish, the parachordal lymphangioblasts were absent from the horizontal myoecytum at 48 hpf, and in stage 35/36 tadpoles, the prox1-positive cells did not bud dorsally from the PCV to form the DCLV. Thus, the early stages of lymphatic development were abrogated in both fish and frogs, while in mice the initial phases of lymphatic development occurred, and vessel abnormalities were detected later. This suggests that, in mice, CLP24 may act during the later stages of lymphatic differentiation, when the SMC-covered collecting lymph vessels are demarcated from lymph capillaries [Tammela and Alitalo 2010]. More SMC-covered enlarged lymphatic vessels have also been described in mice deficient of the Foxc2 transcription factor or angiopoetin-2, or having a mutant ephrinB2 [Petrova et al. 2004; Makinen et al. 2005; Dellinger et al. 2008]. Although clp24 knockdown caused mild blood vascular defects in zebrafish and frog embryos, such were not found in the Clp24+/− mice.

It remains to be studied why the fish and frog vasculatures are more susceptible to the loss of clp24 when compared with mice. Although there are no close homologs of Clp24 in mice, it is possible that a compensating mechanism allows Clp24+/− mice to pass early lymphatic development, thus explaining the differences between the mouse versus the frog and fish phenotypes. In addition, collecting lymphatic vessels have not been reported in fish, and part of the phenotype we describe [difference in SMC recruitment] is associated with their differentiation. It should also be noted that VEGF-C has a more widespread role in fish compared with mice. Although clp24 knockdown caused mild blood vascular defects in zebrafish and frog embryos, such were not found in the Clp24+/− mice.

We next analyzed any possible interactions between CLP24 and VEGFR-2 or VEGFR-3. CLP24 was found to coimmunoprecipitate with both VEGFR-2 and VEGFR-3 from double-transfected human umbilical vein endothelial cells (HUVECs) and 293T cells, in both the presence and absence of ligand stimulation [Fig. 4A,B, data not shown]. As a negative control, CLP24 did not coimmunoprecipitate with Tie-2 from double-transfected cells [Fig. 4C].
Figure 4. CLP24 interacts physically with VEGFR-2 and VEGFR-3 and modulates CREB phosphorylation. [A–C] HUVECs transfected with CLP24-EGFP together with VEGFR-2 [A], VEGFR-3 [B], or Tie2 [C] retrovirus were starved, stimulated 15 min with either VEGF-E [A], VEGF-C [B], or COMP-Ang1 [C], and analyzed by immunoblotting for phospho-CREB [pCREB] [D], total CREB [E], and β-actin [for equal loading]. [F–I] Wild-type [G,I] or CLP24−/− [F,H] endothelial cells were stimulated with VEGF and stained for pCREB. [J–O] Untransfected [J,K] and CLP24-EGFP retrovirus transfected [M–O] intestinal LECs were stimulated with VEGF-C156S [K,N] or VEGF-E [L,O], and were stained for pCREB. CREB is phosphorylated in endothelial cells after stimulation of VEGFR-3 [K] and VEGFR-2 [L], and at higher levels in untransfected cells (arrowheads) than in CLP24-EGFP-expressing cells [N,O]. Nuclei were stained with DAPI.

The lymphatic phenotype of Clp24−/− mice was more pronounced when one allele of Vegfr2 or Vegfr3 was also deleted. Interestingly, CLP24 modulated signaling through VEGFR-2 and VEGFR-3, as phosphorylation of CREB was enhanced when Clp24 was deleted, but was reduced when CLP24 was overexpressed. CREB phosphorylation has been linked to increased cell survival (Lee et al. 2009), which could partly explain the observed enlargement of lymphatic vessels in the Clp24−/− mice. We found that CLP24 coimmunoprecipitated with VEGFR-2 and VEGFR-3 from endothelial cells, suggesting a possibility that CLP24 directly regulates VEGFR-2/VEGFR-3 function. However, further studies are required to unravel the mechanism of CLP24-mediated modulation of VEGFR-2/VEGFR-3 signaling.

Overexpression of VEGFs is associated with pathological activation of the VEGF-2 and VEGF-3 signaling pathways. Blocking of the VEGF–VEGFR-2 pathway is the first anti-angiogenic therapy that is being increasingly used to treat human diseases (Crawford and Ferrara 2009). The present study discovers CLP24 as a novel modulator of VEGF-2 and VEGF-3 signaling, and indicates that CLP24 has an essential function in the lymphatic vasculature, while the possible role of CLP24 in pathological angiogenesis remains to be studied. In conclusion, our results suggest that different effectors are recruited to VEGF-2 and VEGF-3 to control the diverse downstream functions of VEGF/VEGF-C signaling in lymphatic versus blood vessels.

Materials and methods

Cell culture, reagents, immunoblotting, immunofluorescence

Cell culture, retrovirus production, immunoblotting, and immunofluorescence are described previously (Saharinen et al. 2008), and antibodies and growth factor stimulations are described in the Supplemental Material. Tie2, VEGFR-2, VEGFR-3, CLP24-EGFP, and CLP24-V5 cDNAs were cloned into pMXs vector (a generous gift from Dr. Toshio Kitamura, University of Tokyo). Mouse lung endothelial cells were isolated as explained previously (Shalaby et al. 1995), Tie1-lz (Shalaby et al. 1995), Tie2-lz (Dumont et al. 1998), and COMP-Ang1 (Dumont et al. 1998), or COMP-Ang1 (Shalaby et al. 1995), Tie2-Cre (Gustafsson et al. 2001), and PGK-Cre (Lallemand et al. 1998) mice were deleted. Interestingly, CLP24 modulated signaling through VEGFR-2 and VEGFR-3, as phosphorylation of CREB was enhanced when Clp24 was deleted, but was reduced when CLP24 was overexpressed. CREB phosphorylation has been linked to increased cell survival (Lee et al. 2009), which could partly explain the observed enlargement of lymphatic vessels in the Clp24−/− mice. We found that CLP24 coimmunoprecipitated with VEGFR-2 and VEGFR-3 from endothelial cells, suggesting a possibility that CLP24 directly regulates VEGFR-2/VEGFR-3 function. However, further studies are required to unravel the mechanism of CLP24-mediated modulation of VEGFR-2/VEGFR-3 signaling.

Overexpression of VEGFs is associated with pathological activation of the VEGF-2 and VEGF-3 signaling pathways. Blocking of the VEGF–VEGFR-2 pathway is the first anti-angiogenic therapy that is being increasingly used to treat human diseases (Crawford and Ferrara 2009). The present study discovers CLP24 as a novel modulator of VEGF-2 and VEGF-3 signaling, and indicates that CLP24 has an essential function in the lymphatic vasculature, while the possible role of CLP24 in pathological angiogenesis remains to be studied. In conclusion, our results suggest that different effectors are recruited to VEGF-2 and VEGF-3 to control the diverse downstream functions of VEGF/VEGF-C signaling in lymphatic versus blood vessels.

ISH and scoring of TD and parachordal lymphatic precursor formation in zebrafish embryos

Clp24 ISH was performed as described (Chittenden et al. 2006), and live screening and quantification of TD formation was performed as detailed in the Supplemental Material.

ISH, MO injections, and morphometric and general analysis of the development in X. laevis

Whole-mount ISH using prox1 probe was performed as described previously (Ny et al. 2003) and in the Supplemental Material. The generation and characterization of the Tg(fkh1:GFP) line will be reported elsewhere. The cloning of clp24, the X. laevis clp24 ortholog, and the MO oligos are detailed in the Supplemental Material.

Mouse models

The Vegfr2−/− (Dumont et al. 1998), Vegfr2−/− (Shalaby et al. 1995), Tie2-Cre (Gustafsson et al. 2001), and PGK-Cre (Lallemand et al. 1998) mice...
were used. The conditional Clp24 gene targeted mice were produced at GenOway (http://www.genoway.com). Immunohistochemistry, whole-mount staining, and LacZ staining of mouse tissues were done as in Petrova et al. [2004].

**ISH of mouse tissues**

ISH was performed using digoxigenin-labeled probes on 16- to 30-μm frozen sections of mouse embryos as detailed in the Supplemental Material.

**Acknowledgments**

We thank the Biomedicum Helsinki and the Haartman Institute Animal Facilities for excellent animal husbandry; Niina Ihalainen, Kirsi Mänttäri, Ville Pihlajaniemi, Tapio Tainola, Rieke Tembusyver, and the Biomedicum Molecular Imaging Unit for expert technical assistance; Dr. G. Y. Koh for COMP-Ang1, and Dr. Juha Partanen and Dr. Hannu Saritola for professional advice. This work was supported by grants from the European Union (Lymphangiogenics, LSHG-CT-2004-503573), the Finnish Academy (213327 and 130446 to P.S.), and the Henrik Kuninag Foundation, and by grants (to H.H.) from the Finnish Cancer Organizations, Jenny and Antti Wihuri Foundation, the Finnish Heart Association, and Orion-Farmos Research Foundation.

**References**

Adams RH, Alitalo K. 2007. Molecular regulation of angiogenesis and lymphangiogenesis. *Nat Rev Mol Cell Biol* 8: 464–478.

Chittenden TW, Claes F, Lanahan AA, Autiero M, Palac RT, Tkachenko EV, Ellenben A, Ruiz de Almodovar C, Dedkov E, Tomanek R, et al. 2006. Selective regulation of arterial branching morphogenesis by synectin. *Dev Cell* 10: 783–795.

Christoforou N, Miller RA, Hill CM, Jie CC, McCallion AS, Gearhart JD. 2008. Mouse ES cell-derived cardiac precursor cells are multipotent and facilitate identification of novel cardiac genes. *J Clin Invest* 118: 894–903.

Crawford Y, Ferrara N. 2009. VEGF inhibition: Insights from preclinical and clinical studies. *Cell Tissue Res* 335: 261–269.

Dellinger M, Hunter R, Bernas M, Gale N, Vancopoulous G, Erickson R, Witte M. 2008. Defective remodeling and maturation of the lymphatic vasculature in Angiopoietin-2 deficient mice. *Dev Biol* 319: 309–320.

Dumont DJ, Jussila L, Taipale J, Lymboussaki A, Mustonen T, Pajusola K, Beerbaum M, Alitalo K. 1998. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. *J Cell Sci* 111: 747–756.

Lee HT, Chang YC, Tu YF, Huang CC. 2009. VEGF-A/VEGFR-2 signaling leading to cAMP response element-binding protein phosphorylation is a shared pathway underlying the protective effect of preconditioning on neurons and endothelial cells. *J Neurosci* 29: 4356–4368.

Makinen T, Adams RH, Bailey J, Lu Q, Ziemiecki A, Alitalo K, Klein R, Wilkinson GA. 2005. PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. *Genes & Dev* 19: 397–410.

Nagy JA, Vassele E, Feng D, Sundberg C, Brown LF, Detmar MJ, Lawitts JA, Benjamin L, Tan X, Manseau EJ, et al. 2002. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. *J Exp Med* 196: 1497–1506.

Ny A, Koch M, Schneider M, Neven E, Tong RT, Maity S, Fischer C, Plaisance S, Lambrechts D, Heligon C, et al. 2005. A genetic *Xenopus laevis* tadpole model to study lymphangiogenesis. *Nat Med* 11: 998–1004.

Petrova TV, Karpanen T, Normrem C, Mellor R, Tamakoshi T, Finegold D, Ferrell R, Kerjaschki D, Mortimer P, Yla-Herttuala S, et al. 2004. Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. *Nat Med* 10: 974–981.

Reynolds LE, Hodivala-Dille K. 2006. Primary mouse endothelial cell culture for assays of angiogenesis. *Methods Mol Biol* 120: 503–509.

Saharinen P, Eklund L, Miettinen J, Wirkkala R, Anisimov A, Winderlich M, Notebae A, Vestweber D, Deutsch U, Koh GY, et al. 2008. Angiopoietins assemble distinct Tie2 signalling complexes in endothelial–cell–cell and cell–matrix contacts. *Nat Cell Biol* 10: 527–537.

Shalaby F, Rossant J, Yamaguchi TP, Gottsstein M, Wu XF, Breitman ML, Schuh AC. 1995. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. *Nature* 376: 62–66.

Tammela T, Alitalo K. 2010. Lymphangiogenesis: Molecular mechanisms and future promise. *Cell* 140: 460–476.

Tammela T, Zarkada G, Wallgard E, Muramaki A, Suchting S, Wirzenius M, Waltari M, Hellstrom M, Schomber T, Peltonen R, et al. 2008. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. *Nature* 454: 656–660.

Wick N, Saharinen P, Saharinen J, Gunnoho E, Steiner CW, Raab I, Stokic D, Giovanoli P, Buchsbaum S, Burchard A, et al. 2007. Transcriptional comparison of human dermal lymphatic endothelial cells ex vivo and in vitro. *Physiol Genomics* 28: 179–192.

Wirzenius M, Tammela T, Uutela M, He Y, Odorioso T, Zambruno G, Nagy JA, Dvorak HF, Yla-Herttuala S, Shibuya M, et al. 2007. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. *J Exp Med* 204: 1431–1440.
Claudin-like protein 24 interacts with the VEGFR-2 and VEGFR-3 pathways and regulates lymphatic vessel development

Pipsa Saharinen, Hanna Helotera, Juho Miettinen, et al.

*Genes Dev.* 2010, 24:
Access the most recent version at doi:10.1101/gad.565010